Trial
NCT02641002
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
Leukemia, Myeloid, Acute
Intervention
CC-90002
Why stopped
Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-18